Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Pacira BioSciences, Inc.
PCRXCurrent price
20.55 USD
-0.57 USD (-2.70%)
Last closed
21.13 USD
Company
www.pacira.com
ISIN
US6951271005
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
917 461 504 USD
Yield for 12 month
-36.44 %
1Y
3Y
5Y
10Y
15Y
PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Address: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18.13 USDP/E ratio
–Dividend Yield
–Current Year
+674 978 000 USD
Last Year
+666 823 000 USD
Current Quarter
+168 573 000 USD
Last Quarter
+178 023 000 USD
Current Year
+490 309 000 USD
Last Year
+467 528 000 USD
Current Quarter
+129 709 000 USD
Last Quarter
+119 439 000 USD
Key Figures PCRX
1 year
3 years
5 years
10 years
EBITDA
178 032 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
4.17 %
PEG Ratio
-3.83
Return On Equity TTM
-11.48 %
Wall Street Target Price
18.13 USD
Revenue TTM
694 956 992 USD
Book Value
16.24 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
2.80 %
Dividend Yield
–
Gross Profit TTM
393 231 000 USD
Earnings per share
-1.98 USD
Diluted Eps TTM
-1.98 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-24.50 %
Profit Margin
-13.06 %
Dividend Analytics PCRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
5.79
Enterprise Value Revenue
1.59
Price Sales TTM
1.32
Enterprise Value EBITDA
33.14
Price Book MRQ
1.22
Financials PCRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PCRX
For 52 weeks
11.16 USD
35.95 USD
50 Day MA
17.27 USD
Shares Short Prior Month
4 822 169
200 Day MA
21.95 USD
Short Ratio
8.62
Shares Short
4 795 767
Short Percent
15.12 %
BeatStart